Equillium Announces Interim Safety Data And Reduction In Proteinuria For Lupus Patients Treated With Itolizumab In The EQUALISE Study Presented At The ACR Annual Meeting

by | Nov 2, 2021 | Uncategorized | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.